StoneChecker gets CE Mark for its kidney stone analysis software

Imaging software developer StoneChecker gets CE Mark for its kidney stone analysis product.

StoneChecker, a U.K.-based medical software developer that is part of Flying Brands, said it has received a CE Mark for its software that analyzes kidney stones.

The medical imaging software provides a detailed analysis of kidney stones that gives physicians and clinicians critical information to formulate the most effective treatment for each patient, StockMarketWire reported.

The product uses a TexRAD developed algorithm to examine kidney stone heterogeneity and "texture" not visible to the naked eye, according to the company’s website.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The approval opens the door for StoneChecker to begin marketing the software across Europe. 

"Obtaining a CE mark for StoneChecker Software's first product comfortably before the end of the year target has been a significant accomplishment for the agile multidisciplinary Stone Checker team,” Trevor Brown, the CEO of Flying Brands, said in a statement. “I share the team's excitement as we prepare to approach the markets now available to us.”


Suggested Articles

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

A new $100 million (€85 million) capital fund out of Germany has closed and is looking for “ground-breaking” heart disease tech.